Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression

Read full text Summarise with VIRAT
Authors: Ha-Song Bae, Yun‐Jeong Seo, Eun‐Bi Kim, Hyoung‐Min Park, I‐Hsuan Liu, J. Eugene Lee, Jae‐Young Kim
Cited by: 0
References: 54

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free quantitative proteomic profiling. AS1411 treatment significantly reduced TNBC cell viability and migration. To uncover the underlying mechanisms, we performed global proteomic analysis of AS1411‐treated TNBC cells. Bioinformatic analysis of differentially expressed proteins (DEPs) revealed enrichment of tumor‐associated signaling pathways and protein–protein interaction networks regulated by AS1411. Among the DEPs, ATPase H + ‐transporting accessory protein 1 (ATP6AP1) was markedly downregulated in AS1411‐treated TNBC cells. Functional studies demonstrated that ATP6AP1 knockdown suppressed TNBC cell proliferation and migration, whereas its overexpression enhanced tumorigenic phenotypes. Importantly, modulation of ATP6AP1 expression showed minimal effects on normal breast epithelial cells. Collectively, these findings identify ATP6AP1 as a key downstream mediator of AS1411 and support its potential as a therapeutic target in TNBC.

Fields of Study & Subjects

Breast Cancer Treatment Studies Advanced Proteomics Techniques and Applications Advanced biosensing and bioanalysis techniques

Publication details

Journal / source
PROTEOMICS
Volume
26
Issue
7
Pages
28–41
Publication date
27 March 2026
Language
EN